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Abstract
Background:  Two planned trials of pre-exposure prophylaxis tenofovir in Cambodia and
Cameroon to prevent HIV infection in high-risk populations were closed due to activist pressure
on host country governments. The international news media contributed substantially as the
primary source of knowledge transfer regarding the trials. We aimed to characterize the nature of
reporting, specifically focusing on the issues identified by media reports regarding each trial.
Methods: With the aid of an information specialist, we searched 3 electronic media databases, 5
electronic medical databases and extensively searched the Internet. In addition we contacted
stakeholder groups. We included media reports addressing the trial closures, the reasons for the
trial closures, and who was interviewed. We extracted data using content analysis independently,
in duplicate.
Results: We included 24 reports on the Cambodian trial closure and 13 reports on the Cameroon
trial closure. One academic news account incorrectly reported that it was an HIV vaccine trial that
closed early. The primary reasons cited for the Cambodian trial closure were: a lack of medical
insurance for trial related injuries (71%); human rights considerations (71%); study protocol
concerns (46%); general suspicions regarding trial location (37%) and inadequate prevention
counseling (29%). The primary reasons cited for the Cameroon trial closure were: inadequate
access to care for seroconverters (69%); participants not sufficiently informed of risks (69%);
inadequate number of staff (46%); participants being exploited (46%) and an unethical study design
(38%). Only 3/23 (13%) reports acknowledged interviewing research personnel regarding the
Cambodian trial, while 4/13 (30.8%) reports interviewed researchers involved in the Cameroon
trial.
Conclusion: Our review indicates that the issues addressed and validity of the media reports of
these trials is highly variable. Given the potential impact of the media in formulation of health policy
related to HIV, efforts are needed to effectively engage the media during periods of controversy in
the HIV/AIDS epidemic.
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Background
With almost 5 million new HIV infections and 3 million
AIDS deaths occurring every year worldwide – almost 600
every hour -, the development of safe, effective, and acces-
sible prevention methods has become one of the most
urgent global public health needs[1]. One innovative
method, aimed at reducing HIV infection through chem-
oprophylaxis, is the use of the antiretroviral drug tenofo-
vir (Viread), a nucleotide reverse transcriptase inhibitor
produced by Gilead Sciences Inc. Tenofovir has been cho-
sen as a promising agent for Pre-exposure Prophylaxis
(PREP) therapy for several reasons: it is taken once daily,
can be taken without food, and also has a strong safety
record, limited side effects, and a favorable resistance pro-
file in HIV patients.
Research in animals indicates that tenofovir used as a
PREP may be effective in reducing the risk of HIV infec-
tion[2,3], although recent data have questioned the lon-
gevity of tenofovir's protective effect if there is one[4]. In
order to determine if tenofovir may prevent HIV infection
in humans, the National Institutes of Health, the Bill and
Melinda Gates Foundation and the Centres for Disease
Control funded a series of randomized trials (See Table 1).
The conduct of these trials have, however, received wide-
spread criticism by activist groups citing ethical concerns
and a lack of community involvement in the planning of
the trials[5,6]. This emerging opposition has halted the
progress of 2 PREP trials, in Cambodia and Cameroon,
and threatened the stability of planned PREP trials, and
related recruiting effort, in other developing nations[7].
Trial closures
The first trial to close early was a randomized trial to assess
the safety and efficacy of tenofovir as a PREP agent in
Commercial Sex Workers (CSWs) in Phnom Penh, Cam-
bodia. The trial planned to recruit 960 CSWs and was led
by investigators from the United States (US) and Aus-
tralia. In July 2004, however, a protest staged at the XV
International AIDS Society conference in Bangkok, Thai-
land, brought worldwide media attention to the tri-
als[8,9]. International activist and local representatives of
participant groups led the protest. This protest, as well as
subsequent demonstrations directed at the Cambodian
Ministry of Health, resulted in the early closure of the trial
by the Cambodian Prime Minister, prior to recruitment.
The Cambodian Ministry of Health has provided no offi-
cial reasons for their decision to cancel the trial.
In February, 2005, an extension site of the PREP trial in
Cameroon was halted by the Cameroon national Ministry
of Public Health[6]. The trial was being conducted by
Family Health International (FHI) and had begun recruit-
ing participants. At the time of closure, the trial had
enrolled 400 high-risk sexual behaviour participants. In
this case, media attention again acted as a catalyst to rais-
ing concerns about the quality of treatment provided to
participants and the quality of care that might be provided
afterwards. Protests, led by ACT-UP Paris, an international
AIDS activist group based in several countries, and collab-
orating with Réseau Éthique Droit et Santé (REDS), a
Cameroon based AIDS activist group highlighted the con-
cerns with the conduct of the trial and delivery of care[10].
A documentary examining the activists' allegations aired
on French TV-2 and made the trial international news. In
response to allegations of trial misconduct and ethical
violations, the Cameroon government established an
independent inquiry into the trial conduct. The independ-
ent inquiry reported on February 23, 2005, that the trial
cannot proceed without regular reporting and a formal
study site accreditation for the satellite trial clinic[11],
issues that that had not been addressed by the activist
groups or media. The committee did however, identify
that many of the allegations made by the media about a
lack of safety were false. The inquiry has since recom-
mended that the trials resume after the trial administra-
tors dealt with the reporting issues and attain site
accreditation. ACT-UP Paris reports that they will con-
tinue to protest the PREP trials taking place in other
countries[12].
The media's role as a disseminator of scientific research is
particularly important in areas of scientific con-
duct[13,14]. Because no peer-reviewed publication had
been published at the time of conducting this study and
the media was a strong catalyst in bringing attention to
these trials, we aimed to characterize the nature of their
reporting. We determined the sources of information that
the media utilized in reporting on the tenofovir trial and
the extent to which they consulted activists, researchers
and participants involved in the trial.
Methods
In order to identify all relevant media articles, we searched
3 media databases (POPLINE, PROQUEST and LexisN-
exis), 5 electronic medical databases (AMED, CINAHL, E-
Psyche, EMBASE and MEDLINE) as well as extensively
searched the Internet using Google from inception to
March 10, 2005. Our specific search terms included, but
not limited to: "tenofovir", "viread", "Gilead", "Cambo-
dia" and "Cameroon." We limited articles to those pub-
lished in the English language. We contacted advocacy
agencies and FHI to determine recent interviews they may
have provided. We additionally reviewed CDC factsheets.
To be included in our review, articles had to report on the
trial controversy and closures in Cambodia or Cameroon.
We included articles from any media source, but excluded
non-media articles posted on Non-Government Organi-
zation (NGO) and activist websites as these containBMC International Health and Human Rights 2005, 5:6 http://www.biomedcentral.com/1472-698X/5/6
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mostly blogs or position papers and are not intended to
be objective. We additionally excluded articles addressing
the trial stopped in Nigeria, since this trial was stopped by
FHI for logistical reasons, as well as the planned trials of
PREP in other developing countries, because they have
not been halted at the time we conducted our search [7].
Three authors independently reviewed articles and
reviewed them for relevance (PW, BR, EM). Using content
analysis, we developed a coding template and extracted
the following information from each article: source, date,
location of article, author of article, individuals cited,
organizations cited, events reported, and source of evi-
dence. We extracted data on the initial coding template
through a first reading of the articles to identify major
themes. We agreed on the theme categories through con-
sensus. We then reread the articles and coded them appro-
priately independently, in duplicate. We focused on
reporting the claims and counter-claims reported con-
cerning the trials. We aimed to determine the extent to
which media reports sought input from stakeholders. As
much misleading information was available on the inter-
net through web-blogs, we believed that contact with
stakeholders would provide greater inferences into the
actual reasons for contentiousness or conduct of the trials.
We specifically determined how many articles reported
speaking with the following individuals involved in the
trial closures: activist groups, researcher groups involved
in the trial, local ministry officials and participants. All
disagreements were resolved by consensus.
Results
Our systematic searches yielded 52 relevant articles
addressing the trial in Cambodia. We excluded 22, leaving
30 reports, of which 6 are duplicates. In total, we included
24 distinct, original reports addressing the Cambodian
trial [15-34]. We included 13 reports that specifically
addressed the trials in Cameroon [33,35-45].
Allegations
Cambodia (See Additional file 1)
Thirteen of the Cambodian reports alluded directly to the
Prime minister (PM), Hun Sen [5,8,19,21-
23,27,29,30,46-48]. The PM was quoted numerous times
as being concerned with the study's effects on the human
rights of the Cambodian people. With pressure from the
Cambodian Sex Workers (CSW) to suspend the study, the
PM finally conceded and the trial was halted in August
2004. The representatives from the CSW NGO, Women's
Network for Unity, were against using CSWs from poor
countries like Cambodia for experimental drug testing.
Numerous allegations were made supporting the early ter-
mination of the trial and are outlined in Additional file 1.
Most were made by CSWs and members of various activist
groups opposed to the study. Seventeen reports discussed
the demand for 30–40 years of medical insurance to coun-
ter any adverse events [15-17,22,25-31,33-35,49,50]. Sev-
enteen papers referred to the claim that some aspects of
the study violated basic human rights [5,8,16,19,22-
24,27-30,47,48,51]. Twelve reports, in particular, dis-
cussed the allegations regarding the participation and
potential 'exploitation' of an already vulnerable popula-
tion [5,16,17,19,23,26,27,29,30,48]. Eleven reports dis-
cussed claims made against the study's protocol. For
potential participants and many activists, the use of a pla-
cebo or a 'dummy pill' predominantly became an ethical
concern [5,8,21,24,27,28,30,33,51-53]. Nine reports dis-
cussed suspicions regarding the need to run the trial in
Cambodia when there were high-risk populations resid-
ing in the US and Europe [5,16,19,22,26,30,47,50,52].
Finally, seven reports discussed the allegations that
researchers were purposefully providing insufficient
counseling and educational resources, ensuring that some
women would, in fact become HIV positive during the
trial [5,16,23,27,28,33,52]. Of note, one news report pub-
lished in an academic journal, inaccurately reported that
tenofovir was a vaccine[31].
Counter claims
The demand for long term medical insurance was counter-
claimed by an investigator affiliated with the trial in 1
Table 1: Current tenofovir PREP Studies
Study Location Population Group Sponsor Study Goal Expected Initial Results
Cambodia Commercial sex workers 960 volunteers NIH Safety & efficacy 2007
Cameroon, Ghana High-risk women 800 volunteers FHI Safety & efficacy 2007
Malawi High-risk men 500 volunteers FHI Safety & efficacy 2007
Botswana Young adults 1,200 volunteers CDC Safety &efficacy 2007
Thailand Injection drug users 1,600 volunteers CDC Safety & efficacy 2007
United States Men who have sex with men CDC Safety 2007
Peru Men who have sex with men 2,100 volunteers NIH Safety & efficacy 2008BMC International Health and Human Rights 2005, 5:6 http://www.biomedcentral.com/1472-698X/5/6
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report[50]. She mentioned that this appeal was impossi-
ble to meet due to the enormous costs this would entail.
She further mentions that there is no place in the world,
where participants in clinical trials receive coverage for
life. A representative from FHI directly counters the allega-
tions made concerning the violation of human rights[47].
The FHI representative countered that the sex workers
involved in the trial are offered an enhanced standard of
care well beyond what is typically offered in Cambodia
and other HIV prevention trials. No investigators or offi-
cials were reported responding to the allegations regard-
ing the use of a placebo nor the claim that counseling is
purposely limited to ensure some seroconversions.
Cameroon (see Additional file 2)
There were 13 reports addressing the tenofovir trial in
Cameroon [12,33,35-37,39-45,54]. Nine reported allega-
tions that there was no care for those who seroconvert
during the trial [12,33,35-37,39-41,54]. The charge that
participants are not being sufficiently informed of the
risks involved was reported in 9 articles [12,33,35-
37,40,41,43,44]. Other major allegations included an
inadequate number of support staff (6/13) [12,36,39-
41,54], participants being exploited and treated like
'guinea pigs'(6/13) [12,36,39-41,54], an unethical study
design (5/13) [12,36,40-42,44] and finally, the belief that
trial is only being conducted in Cameroon to promote
Gilead's commercial prospect (5/13) [12,40-42,44].
Counter claims
Two reports interviewed investigators who directly
responded to the claim that no help is provided for those
who seroconvert during the trial [36,43]. The study co-
ordinator in Douala was cited, saying all volunteers who
have become infected are referred to approved medical
centers for treatment[36]. A representatives from FHI in
another report [43], responded citing that study-support
services are offered and that women can decide if they
want to continue on this path. In addition, it was reported
that women have access to medical care and treatment
including referral to services where they can receive care
for HIV. The representative emphasized that women who
have volunteered to participate will have "life-long access
to HIV care and treatment". To counter the claim that par-
ticipants are not fully nor sufficiently informed of the risks
involved, an FHI representative in one report directly
responds to this allegation. She states that all potential
participants "were counseled before the trial started to
make sure they understood the potential risks and bene-
fits of study participation" [43].
Sources of information (see Table 2)
Cambodia
In order to evaluate the soundness of the reports, we iden-
tified the source of the information to determine whom,
if anyone had been interviewed. Potential subjects for the
interviews included trial investigators, potential partici-
pants (ie. CSWs), representatives or activist group mem-
bers. Of 24 reports, 14 did not identify any primary source
of information [8,16,21-23,27-30,33,50,52,55,56]. In 3
reports trial investigators or officials were interviewed
[47,48,50] All investigators emphasized that the concur-
rent trial care provided was beyond the standard of care in
Cambodia and in-addition to what is offered in other HIV
prevention trials.
One report interviewed potential participants [24]. In
three reports that cited activists, their comments came
from web blogs [5,26,53]. Representatives of NGOs were
interviewed in one report [48].
Cameroon
Of the 13 reports, 4 did not report a primary source of
information[33,35,44,45]. Two reports interviewed both
researchers and opponents[36,37]. Four reports concern-
ing the Cameroon trials surveyed investiga-
tors[36,37,41,43]. There were no interviews with
potential participants in any reports. An interview with a
participant representative was recorded in one report [36]
and HIV activists in 6 reports, either in person or through
Internet forums [12,36,37,40,42,54].
Discussion
The findings of this review should be of interest to clinical
trialists, advocates and policy makers. The media are
important communicators of information and can raise
Table 2: Sources of information cited in media reports
Study Total Investigator Potential 
participant
Representatives of 
participant groups
Activist group Others
Cambodia 24 3 (12.5%) 1 (4.1%) 1 (4.1%) 3 (12.5%) 3 (12.5%) NIAID representative;
Cambodian AIDS authority;
Bio-consultant
Cameroon 13 4 (30.8%) 0 1 (7.7%) 6 (46.2%) 1 (7.7%) Local physicianBMC International Health and Human Rights 2005, 5:6 http://www.biomedcentral.com/1472-698X/5/6
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awareness of emerging issues concerning health and
risk[57] We observed that the media brought forth a vari-
ety of concerns related to the conduct of the trials in both
Cambodia and Cameroon. In several instances these con-
cerns were not supported by evidence and were possibly
inaccurate. We also observed that the media involved
stakeholders to a comparatively small degree, suggesting
that the viewpoints they reported may not accurately rep-
resent the views of all those concerned about the conduct
of the trial. Given the potential impact of the media
reporting on the conduct of future tenofovir trials, the
nature of their reporting deserves closer scrutiny.
There are several limitations to consider in interpreting
our review. Although we systematically searched many
databases and extensively searched the Internet, it is pos-
sible that we were unable to identify some reports. Our
searches were limited to the English and French lan-
guages, and as both Cambodia and Cameroon have
media in other languages, we may have missed articles
published in their respective languages. We conducted a
content analysis to identify issues that we deemed trial
related. It is possible that other issues exist, and that other
individuals were interviewed, but were not reported in the
articles. There are also several strengths to consider in
interpreting our review. This is, we believe, the first sys-
tematic review to assess media reporting related to the
closed trials. We conducted extensive searches and
extracted data independently, in duplicate, to remove
investigator driven biases. We spoke with representatives
from each stakeholder group to determine if they were
aware of additional reports, as well as searched the CDC
reports.
The media reports consistently reported concerns with
ethical issues in the conduct of the trials. Both the Cambo-
dian reports and the Cameroon reports cite access to
appropriate standards of care for those who become
infected during the trial and appropriate standard of
prophylaxis. Indeed these same issues are being echoed in
the impending trial of tenofovir in drug users in Thai-
land[9]. Further to this, most media reports regarding
both trials reported that participants were not fully aware
of the risks involved with participation. Clinical trialist's
planning prevention trials, whether of chemoprophylaxis
or microbicides should be aware that many populations
are not in situations in which to make informed decisions
about clinical trial methodologies and the risks related to
trial participation. Enrolling these communities in devel-
oping nations requires the establishment of community
advisory boards and gender advisory boards, to ensure
that the information is being provided, and interpreted, in
an accurate manner[58,59].
The tenofovir trial media attention does however, have
implications for prevention trials, such as HIV vaccines.
Prevention methods are urgently needed to stem the
onslaught of new HIV infections. Novel interventions,
such as vaccines, microbicides, or chemoprophylaxis, will
all require clinical trial validation. The media reporting of
the tenofovir trials may threaten trial recruitment and
potentially stigmatize trial participation.
There are important qualitative differences between the
media reports of the trial in Cambodia compared to the
trial in Cameroon. It is important to note that the trial in
Cambodia was closed before recruiting any participants,
whereas the trial in Cameroon had met its recruitment
goals (n = 400). Most criticisms regarding the trial in Cam-
bodia related to a lack of access to adequate care during
the trials and post-trial, for those who may become
infected. These concerns for potential infections appeared
to be the overriding concerns as activists cited that these
trials would be conducted to a different level of protection
and insurance if they were conducted in a developed
country. The articles addressing the trial closure in Cam-
eroon were somewhat different and were largely based on
reports of trial misconduct, in the context of inadequate
informed consent, inadequate access to counseling and
inadequate access to male and female condoms. The trials
did however; have overlapping concerns about the ethical
standards for trials in developing nations compared to
Western nations and the protection of the participants
human rights.
The tenofovir trials raise important questions about the
relationship between researchers, participants and activ-
ists[60]. With worldwide media attention, these trial clo-
sures demonstrate the ability of activists to engage the
media and bring about important consequences for the
conduct of trials. Activists are experienced at bringing
about change and have strong lobbying potential that can
impact researchers and the HIV community. The activist
communities have substantial experience using the media
to address topics of importance in HIV and are well-edu-
cated regarding ethical standards and trial designs.
Indeed, it is important to note that several of the ethical
issues raised in the media reports: standard of care, access
to proven prophylaxis and access to treatment for sero-
converters; have not yet been resolved within the aca-
demic community [61,62].
The Media, accuracy of communication and influence on 
policy
The media plays an important role at the interface of sci-
ence and policy. Indeed, the media has been utilized to
change behaviour in HIV public health campaigns[60].
Most scientists and non-scientists receive information
from media sources [63]. One policy making model spe-BMC International Health and Human Rights 2005, 5:6 http://www.biomedcentral.com/1472-698X/5/6
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cifically addresses this issue and describes how informa-
tion is generated by researchers and then disseminated by
advocacy networks and the media [64]. The information
provided by the media is eventually interpreted by policy
makers and government officials, and those informally
involved, such as patient groups and stakeholder groups.
Although media information provides weak levels of evi-
dence, multiple sources of media information may
strengthen personal inferences. The interpretation of this
information is influenced by the value systems of the indi-
viduals receiving the information.
This review displays the important role that the media
play in knowledge dissemination, and the responsibilities
that they have in accurate reporting. In our review, 20
reports did not acknowledge interviewing any stakeholder
and in no case did any report interview those supporting
the trials and those against the trials. It is impossible to
determine the extent to which the allegations made
regarding the trials were wholly inaccurate. Our review
contributes to a large body of evidence indicating that the
media at times misrepresents scientific information and
presents the science in a varied manner [65], as in the case
of the trial in Cameroon where the reports suggest inade-
quate counseling and informed consent sheets that were
not available in the local languages, issues that were not
upheld by the ministry of health. It should be noted how-
ever, that not only standard news sources, but also aca-
demic news sources were susceptible to inaccuracies in
their reporting. In one case, a top academic journal
reported tenofovir to be a vaccine trial[31].
Indeed the media plays an important role in highlighting
HIV issues so that it remains of topic of high profile and
can be used as a strategy to convey AIDS awareness and
prevention[60]. The media has a responsibility to report
in a factual and objective manner [66]. Media agencies
should be engaged to educate them on trial protocols and
ethics so that reporting can be discriminating. The Inter-
national AIDS Vaccine Initiative (IAVI) has now initiated
training with journalists to ensure knowledgeable report-
ing related to vaccines [67]. This seems like a logical step
towards ensuring adequate reporting of prevention trials.
We recommend further analysis of this emerging issue of
media reporting of contentious clinical trials. The impact
of such reporting, as we have described, clearly demon-
strates that it deserves closer attention. Next steps would
engaging journalists involved in the reporting to deter-
mine what strategies clinical trialists, participants and
stakeholders could utilize to improve reporting. An anal-
ysis of the strategies used by stakeholders to provide infor-
mation to the media and the relative successes of these
strategies would also be worth studying.
Conclusion
In conclusion, our review identifies the heterogeneous
reporting of issues related to these trial closures and the
relatively poor involvement of stakeholders for the pur-
pose of interviews. In several instances these concerns
were not supported by evidence and were possibly inaccu-
rate. However, the overall issues reported in the media
reports is a sense of distrust and concern for the well-being
of participants. Given the role of the media in reporting
on the conduct of future prevention trials, serious initia-
tives are warranted to engage the media and preempt dif-
ficulties in the transference of information.
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